Targeting tumor-intrinsic BCL9 reverses immunotherapy resistance by eliciting macrophage-mediated phagocytosis and antigen presentation. (PRJCA047916)
This study aims to investigate how tumor-intrinsic BCL9 expression contributes to immune checkpoint inhibitor (ICI) resistance in hepatocellular carcinoma (HCC), and to explore the mechanisms by which targeting BCL9 with hsBCL9Z96 overcomes ICI resistance in HCC ex vivo and in vivo.
This study aims to investigate how tumor-intrinsic BCL9 expression contributes to immune checkpoint inhibitor (ICI) resistance in hepatocellular carcinoma (HCC), and to explore the mechanisms by which targeting BCL9 with hsBCL9Z96 overcomes ICI resistance in HCC ex vivo and in vivo.